Thallion in $150-million pact to develop Shigamabs
December 18, 2009 by leonardzehr · Leave a Comment
Thallion Pharmaceuticals (TSX:TLN) is teaming up with LFB Biotechnologies of France to develop Shigamabs, Thallion’s product candidate for the treatment of Shigatoxin-producing bacterial, or STEC, infection. The accord, which is expected to close in the first quarter, provides for immediate funding by LFB of costs associated with re-initiating the Shigamabs program. In a statement, Thallion [...]
Listen to BioTuesdays 
